Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years

Authors:

Abstract
Background and Objectives The prognostic implication of symptomatic presentation of gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) remains unclear. Methods Patients who underwent resection of nonfunctional GEP‐NETs (2000–2014) were analyzed. Primary outcomes were overall survival (OS) and distant recurrence‐free survival (RFS). Results Symptomatic presentation was seen in 208 (61%) of 339 patients and was associated with younger age (55 vs. 59 yrs, P = 0.001), higher tumor grade (38% vs. 21%, P = 0.027), presence of lymphovascular invasion (58% vs. 33%, P < 0.001), presence of perineural invasion (54% vs. 29%, P = 0.002), and advanced disease (T3/T4/N1/M1 [63% vs. 44%, P = 0.002]), but not tumor size (2.6 vs. 2.5 cm, P = 0.74). Symptomatic presentation was associated with decreased 3‐yr distant‐RFS (80% vs. 89%, P = 0.012), but not OS. When accounting for adverse features, symptomatic presentation remained independently associated with reduced distant‐RFS (HR 3.51, P = 0.007). On subgroup‐analysis of advanced disease patients, symptomatology was associated with reduced 3‐yr distant‐RFS (67% vs. 79%, P = 0.012) and persisted as an independent risk‐factor for decreased distant‐RFS (HR 3.01, P = 0.027). Conclusions Symptomatic presentation of GEP‐NETs is associated with aggressive features and worse distant‐RFS. Trials assessing adjuvant therapy for advanced GEP‐NETs are needed, and symptomatic presentation may be considered as one inclusion criterion. Following resection, symptomatic presentation should be taken into account when planning surveillance. J. Surg. Oncol. 2016;114:163–169.
Funding Information
  • Katz Foundation

This publication has 16 references indexed in Scilit: